Mabylon AG: Funding, Investors & Team (Sep 2026)
Mabylon AG is a Swiss biotechnology company that is using naturally occurring human antibodies to develop treatments for allergies and neurodegenerative diseases. They use advanced B-cell screening technologies and screen up to 100,000 human samples a year to identify rare antibodies. These human antibodies have the advantage of targeting disease-related areas, as seen in their advanced programs. One of their products, MY006, has been effective in inhibiting IgE binding in peanut allergies and preventing anaphylaxis in mice. Additionally, their lead program for ALS/FTLD targeting TDP-43 has been partnered with SciNeuro Pharmaceuticals.
Mabylon AG has raised $1.5M across 1 funding round on record, the most recent an undisclosed round of $1.5M announced in Sep 2024.
That round is below the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Mabylon AG Company Profile and Key Stats
Latest funding round on record: Sep 2024.
Mabylon AG Funding Rounds
Mabylon AG Founders and Leadership Team
Contact details for the Mabylon AG team: 1 of 1 has an email address on file.
Start 14-day free trial →Mabylon AG Funding Compared to Other Biotechnology Startups
Mabylon AG's latest round of $1.5M is below the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Mabylon AG in Biotechnology and Schlieren
Companies Similar to Mabylon AG
Adaptyv Biosystems developing a protein engineering platform using cell-free synthetic biology and…
At Immitra Bio, we are developing a unique genetic medicine platform that combines two of the most powerful…
compliag is providing agile solutions for regulated industries, including the licencing, manufacturing and…
MoonLake Immunotherapeutics is a biopharmaceutical company in the clinical stage that is developing new…
Isospec Analytics SA is a life science company that aims at simplifying molecular identification. We are…
Cria Technologies reinvents cold-chain transport with high-vacuum insulation technology that offers…
Precise Health is a phage therapy platform that specialises in improving and treating bacterial infections to…
AC Immune is a biopharmaceutical company based in Switzerland that is currently in the clinical stage. They…
AlveoliX provides in-vitro solutions based on proprietary and unique organ-on-chip technologies aimed at…
Combioxin SA is clinical-stage biotech company developing innovative anti-virulence drugs to treat severe…
MindMaze is a digital neurotherapeutic platform that provides digital assessments and therapeutics to treat…
Neurosoft Bioelectronics is developing next-generation soft implantable electrodes to interface with the…
Mabylon AG Funding FAQs
What does Mabylon AG do?
Mabylon AG is a Swiss biotechnology company that is using naturally occurring human antibodies to develop treatments for allergies and neurodegenerative diseases. They use advanced B-cell screening technologies and screen up to 100,000 human samples a year to identify rare antibodies. These human antibodies have the advantage of targeting disease-related areas, as seen in their advanced programs. One of their products, MY006, has been effective in inhibiting IgE binding in peanut allergies and preventing anaphylaxis in mice. Additionally, their lead program for ALS/FTLD targeting TDP-43 has been partnered with SciNeuro Pharmaceuticals.
How much funding has Mabylon AG raised?
Mabylon AG has raised $1.5M across 1 round on record. The most recent is an undisclosed round of $1.5M announced in Sep 2024.
When did Mabylon AG last raise funding?
Mabylon AG's most recent funding round on record is an undisclosed round of $1.5M, announced in Sep 2024.
Who founded Mabylon AG?
FundedIQ lists Alcide Barberis (Founder) at Mabylon AG.
Where is Mabylon AG headquartered?
Mabylon AG is based in Schlieren, Zurich, Switzerland.
How many employees does Mabylon AG have?
Mabylon AG is in the 11-50 employee band.
How does Mabylon AG's funding compare to other Biotechnology startups?
Mabylon AG's latest round of $1.5M is below the $8.0M median round size for Biotechnology companies on FundedIQ across 4,179 tracked companies over the last two years.
About FundedIQ's Mabylon AG Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Mabylon AG is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.